DVS at doses ≥ 50 mg/day significantly improves depressive symptoms compared with placebo. Among the evaluated doses, 200 mg/day consistently showed numerically greater improvements while maintaining acceptable tolerability; however, the certainty of dose differences remains limited, and no definitive "optimal" dose can be established based on the current evidence.
Li et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: